Showing results (791-800 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|March 17, 2007
The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeuticsAthanasios G Papatsoris, Michalis V Karamouzis, Athanasios G Papavassiliou
Molecular Cancer Therapeutics|March 17, 2007
Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivoOlaf R Mook, Frank Baas, Marit B de Wissel, et al.
Molecular Cancer Therapeutics|March 17, 2007
Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2Luigi Carlessi, Giacomo Buscemi, Gary Larson, et al.
Molecular Cancer Therapeutics|March 17, 2007
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trialHuw D Thomas, Christopher R Calabrese, Michael A Batey, et al.
Molecular Cancer Therapeutics|March 17, 2007
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cellsMurielle Mimeault, Sonny L Johansson, Ganesh Vankatraman, et al.
Molecular Cancer Therapeutics|March 17, 2007
Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancerBasil Hassouneh, Mozaffarul Islam, Thomas Nagel, et al.
Molecular Cancer Therapeutics|March 17, 2007
p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3Ronald Pak Cheung Wong, Wing Pui Tsang, Pui Yee Chau, et al.
Molecular Cancer Therapeutics|March 17, 2007
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosisJing Wang, Karen Kuropatwinski, Jennie Hauser, et al.
Molecular Cancer Therapeutics|March 17, 2007
Resistance to c-KIT kinase inhibitors conferred by V654A mutationKathryn G Roberts, Adam F Odell, Ellen M Byrnes, et al.
Molecular Cancer Therapeutics|January 24, 2007
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101Jianming Duan, Jay Friedman, Liesl Nottingham, et al.
Pageof 599